There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > B7-H3


Brief Information

Name:CD276 antigen
Target Synonym:B7H3,CD276,CD276 Molecule,Costimulatory Molecule,4Ig-B7-H3,B7RP-2,PSEC0249,UNQ309/PRO352,B7-H3,CD276 antigen,B7 homolog 3
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Phase 3 Clinical

Product ListCompare or Buy

Part of Bioactivity data

B73-H52E2-Cell-based assay
Human FcRn Heterodimer Protein Cell_Base

Human B7-H3, His Tag (Cat. No. B73-H52E2) inhibits Anti-CD3-induced proliferation of PBMC. The EC50 for this effect is 2.24-3.36 μg/mL (Routinely tested).

Biotinylated Human B7-H3, Fc,AvitagBiotinylated Human B7-H3, Fc,Avitag (Cat. No. B73-H82F5) ELISA bioactivity

Immobilized Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 at 2 μg/mL (100 μL/well) can bind Biotinylated Human B7-H3, Fc,Avitag (Cat. No. B73-H82F5) with a linear range of 0.3-2 ng/mL (QC tested).

Cynomolgus B7-H3, His Tag (Cat. No. ) MALS images

The purity of Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) was more than 90% and the molecular weight of this protein is around 65-85 kDa verified by SEC-MALS.

Cynomolgus B7-H3, His TagCynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) ELISA bioactivity

Immobilized Cynomolgus B7-H3, His Tag (Cat. No. B73-C52Ha) at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human B7-H3 / B7-H3 (4Ig) Antibody, Human IgG1 with a linear range of 0.1-4 ng/mL (QC tested).

Synonym Name

B7-H3,CD276,B7 homolog 3


B7 homolog 3 (B7-H3), a member of the immunoglobulin superfamily, is also known CD276, which contains two Ig-like C2-type (immunoglobulin-like) domains and two Ig-like V-type (immunoglobulin-like) domains. B7-H3 may participate in the regulation of T-cell-mediated immune response. B7-H3 also plays a protective role in tumor cells by inhibiting natural-killer mediated cell lysis as well as a role of marker for detection of neuroblastoma cells. Furthermore, B7-H3 is involved in the development of acute and chronic transplant rejection and in the regulation of lymphocytic activity at mucosal surfaces. It could also play a key role in providing the placenta and fetus with a suitable immunological environment throughout pregnancy.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
MGC-018 MGC-018 Phase 2 Clinical Macrogenics Neoplasms Details
SCRI-CARB7H3 SCRI-CARB7H3 Phase 1 Clinical Seattle Children'S Hospital Central Nervous System Neoplasms; Glioma Details
Monoclonal antibody 8H9 I-124 124I-8H9; 124I-8H9-(B7-H3) Phase 2 Clinical Memorial Sloan Kettering Cancer Center Glioma Details
DS-7300 DS-7300 Phase 2 Clinical Daiichi Sankyo Co Ltd Neoplasms Details
4SCAR-276 4SCAR-276 Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Neoplasms Details
Monoclonal antibody 8H9 I-131 8H9-MAb; 131-I-8H9; 131I-8H9-(B7-H3) Phase 3 Clinical Memorial Sloan Kettering Cancer Center Neuroblastoma; Peritoneal Neoplasms; Neoplasm Metastasis Details
B7-H3 CAR-T cell therapy (Zhejiang University) Phase 2 Clinical Zhejiang University Alumni Association (Singapore) Glioblastoma Details
Enoblituzumab MGA-271 Phase 2 Clinical Macrogenics Head and Neck Neoplasms; Rhabdomyosarcoma; Squamous Cell Carcinoma of Head and Neck; Desmoplastic Small Round Cell Tumor; Carcinoma, Renal Cell; Wilms Tumor; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Osteosarcoma; Neuroblastoma; Prostatic Neoplasms; Sarcoma, Ewing; Melanoma; Carcinoma, Non-Small-Cell Lung Details
Anti-CD276 CAR T-cell therapy (The First Affiliated Hospital of Zhengzhou University) Phase 1 Clinical Stomach Neoplasms; Osteosarcoma; Neuroblastoma; Lung Neoplasms Details
Mirzotamab clezutoclax ABBV-155 Phase 1 Clinical Abbvie Inc Hematologic Neoplasms; Solid tumours Details
177Lu-DTPA-omburtamab Phase 2 Clinical Y-Mabs Solid tumours; Meningeal Neoplasms Details
Omburtamab I-131 Phase 1 Clinical Y-Mabs Central Nervous System Neoplasms; Sarcoma; Neuroblastoma; Brain Neoplasms Details
Orlotamab MGD-009; B7-H3 x CD3 Phase 2 Clinical Macrogenics Mesothelioma; Melanoma; Carcinoma, Non-Small-Cell Lung; Thyroid Neoplasms; Neurofibrosarcoma; Neuroblastoma; Sarcoma; Prostatic Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Sarcoma, Synovial; Urinary Bladder Neoplasms; Wilms Tumor; Pancreatic Neoplasms; Colonic Neoplasms; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Renal Cell; Rhabdomyosarcoma Details

This web search service is supported by Google Inc.